Assessment of early paraprotein response to vincristine-doxorubicin- dexamethasone chemotherapy may help guide therapy in multiple myeloma

David Ross, L. B. To, Noemi Horvath

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Vincristine, doxorubicin and dexamethasone (VAD) are commonly used as the initial chemotherapy in myeloma patients prior to high-dose therapy and autologous stem cell transplantation. We reviewed monoclonal protein responses and survival of 62 patients treated in this way. Among patients with IgG paraprotein, achievement of at least 50% reduction in paraprotein after the first cycle of VAD correlated with significantly better event-free survival at 3 years, compared with those having less than 50% response. We postulate that early paraprotein response may be used to identify high risk patients.

LanguageEnglish
Pages576-578
Number of pages3
JournalInternal Medicine Journal
Volume34
Issue number9-10
DOIs
Publication statusPublished - 1 Sep 2004
Externally publishedYes

Keywords

  • Autologous transplantation
  • Multiple myeloma
  • Paraprotein
  • Prognostic factors

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{634fb246f9da45159eadb9a3d8648de7,
title = "Assessment of early paraprotein response to vincristine-doxorubicin- dexamethasone chemotherapy may help guide therapy in multiple myeloma",
abstract = "Vincristine, doxorubicin and dexamethasone (VAD) are commonly used as the initial chemotherapy in myeloma patients prior to high-dose therapy and autologous stem cell transplantation. We reviewed monoclonal protein responses and survival of 62 patients treated in this way. Among patients with IgG paraprotein, achievement of at least 50{\%} reduction in paraprotein after the first cycle of VAD correlated with significantly better event-free survival at 3 years, compared with those having less than 50{\%} response. We postulate that early paraprotein response may be used to identify high risk patients.",
keywords = "Autologous transplantation, Multiple myeloma, Paraprotein, Prognostic factors",
author = "David Ross and To, {L. B.} and Noemi Horvath",
year = "2004",
month = "9",
day = "1",
doi = "10.1111/j.1445-5994.2004.00689.x",
language = "English",
volume = "34",
pages = "576--578",
journal = "Australian and New Zealand Journal of Medicine",
issn = "1444-0903",
publisher = "Wiley-Blackwell",
number = "9-10",

}

Assessment of early paraprotein response to vincristine-doxorubicin- dexamethasone chemotherapy may help guide therapy in multiple myeloma. / Ross, David; To, L. B.; Horvath, Noemi.

In: Internal Medicine Journal, Vol. 34, No. 9-10, 01.09.2004, p. 576-578.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Assessment of early paraprotein response to vincristine-doxorubicin- dexamethasone chemotherapy may help guide therapy in multiple myeloma

AU - Ross, David

AU - To, L. B.

AU - Horvath, Noemi

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Vincristine, doxorubicin and dexamethasone (VAD) are commonly used as the initial chemotherapy in myeloma patients prior to high-dose therapy and autologous stem cell transplantation. We reviewed monoclonal protein responses and survival of 62 patients treated in this way. Among patients with IgG paraprotein, achievement of at least 50% reduction in paraprotein after the first cycle of VAD correlated with significantly better event-free survival at 3 years, compared with those having less than 50% response. We postulate that early paraprotein response may be used to identify high risk patients.

AB - Vincristine, doxorubicin and dexamethasone (VAD) are commonly used as the initial chemotherapy in myeloma patients prior to high-dose therapy and autologous stem cell transplantation. We reviewed monoclonal protein responses and survival of 62 patients treated in this way. Among patients with IgG paraprotein, achievement of at least 50% reduction in paraprotein after the first cycle of VAD correlated with significantly better event-free survival at 3 years, compared with those having less than 50% response. We postulate that early paraprotein response may be used to identify high risk patients.

KW - Autologous transplantation

KW - Multiple myeloma

KW - Paraprotein

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=8344251663&partnerID=8YFLogxK

U2 - 10.1111/j.1445-5994.2004.00689.x

DO - 10.1111/j.1445-5994.2004.00689.x

M3 - Review article

VL - 34

SP - 576

EP - 578

JO - Australian and New Zealand Journal of Medicine

T2 - Australian and New Zealand Journal of Medicine

JF - Australian and New Zealand Journal of Medicine

SN - 1444-0903

IS - 9-10

ER -